CTOs on the Move

Nanosphere

www.nanosphere.us

 
Nanosphere is dedicated to enhancing medicine by providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. Nanosphere’s platform, the Verigene® System, enables clinicians to rapidly identify and treat the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. Headquartered in Northbrook, Illinois, Nanosphere was founded in 1999 based upon technology developed at Northwestern University by Dr. Robert Letsinger and Dr. Chad Mirkin. In 2007, Nanosphere went public (NASDAQ: NSPH), and has remained committed to continued scientific discovery and innovation with more than 175 patents to its ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Molecular Therapeutics

Molecular Therapeutics, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

hhoaltd

hhoaltd is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.

Nutcracker Therapeutics

Nutcracker Therapeutics is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA therapeutics platform. Armed with this high-tech advantage, we have developed a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with top clinical investigators at several leading institutions across the globe. With our platform`s ability to accelerate the development of life-changing RNA therapeutics, we seek to advance breakthrough RNA therapies at high velocity through all stages of development across a variety of indications. Our technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in capacity scaling and point-of-care delivery over other RNA manufacturing approaches.

Point Biopharma

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer